Drug Trial Radar · NCT01513239
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Last checked: Nov 19, 2026Latest source record: Sep 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,203
Actual
Start
Feb 1, 2012
Primary completion
May 22, 2015
Study completion May 22, 2015
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MK-3415A is the combination of monoclonal antibodies to Clostridium (C.) difficile toxin A (MK-3415) and toxin B (MK-6072). This study will investigate whether: 1) treatment with MK-6072 or MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium Difficile Infection (CDI) recurrence compared with placebo; and 2) MK-6072 and MK-3415A will be generally well tolerated in participants receiving SOC therapy for CDI compared with placebo.
Conditions
- Clostridium Difficile Infection
Interventions
MK-6072Biological
Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
MK-3415ABiological
Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
PlaceboBiological
Single IV infusion of normal saline (0.9% sodium chloride)
SOCDrug
SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With CDI RecurrenceTime frame: 12 weeks
- Percentage of Participants With One or More Adverse Events During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
- Percentage of Participants With One or More Drug-related Adverse Events During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
- Percentage of Participants With One or More Serious Drug-related Adverse Events During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
- Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
- Percentage of Participants With One or More Infusion-specific Adverse Events on the Day of Infusion or the Day After InfusionTime frame: Up to 24 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.